GenSight Biologics S.A.
Biopharma developing gene therapies for retinal neurodegenerative diseases and CNS disorders.
SIGHT | PA
Overview
Corporate Details
- ISIN(s):
- FR0013183985 (+3 more)
- LEI:
- 549300NK4AB8OUEX1F54
- Country:
- France
- Address:
- 74 RUE DU FAUBOURG SAINT-ANTOINE, 75012 PARIS
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
GenSight Biologics S.A. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies. The company targets retinal neurodegenerative diseases and central nervous system disorders. Its therapeutic approach is built on two core technology platforms: a Mitochondrial Targeting Sequence (MTS) and optogenetics. GenSight's lead product candidate, lenadogene nolparvovec (GS010), is in late-stage clinical development for treating Leber Hereditary Optic Neuropathy (LHON). Its second candidate, GS030, utilizes optogenetics to potentially restore vision in patients with diseases such as retinitis pigmentosa and is advancing through clinical trials.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for GenSight Biologics S.A. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-22 19:00 |
Capital/Financing Update
Inside Information / Operations of the issuer (acquisitions, sales...)
|
English | 220.0 KB | |
| 2025-07-22 19:00 |
Share Issue/Capital Change
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
|
French | 207.1 KB | |
| 2025-07-11 11:27 |
Major Shareholding Notification
Franchissement de seuils
|
French | 114.0 KB | |
| 2025-07-03 21:19 |
Share Issue/Capital Change
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
|
French | 247.4 KB | |
| 2025-07-03 21:19 |
Capital/Financing Update
Inside Information / Operations of the issuer (acquisitions, sales...)
|
English | 243.8 KB | |
| 2025-06-26 07:30 |
Regulatory News Service
Inside Information / Other news releases
|
English | 165.8 KB | |
| 2025-06-26 07:30 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 155.9 KB | |
| 2025-06-12 19:02 |
Regulatory News Service
Inside Information / Other news releases
|
English | 207.0 KB | |
| 2025-06-12 19:02 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 176.7 KB | |
| 2025-05-13 22:00 |
Post-Annual General Meeting Information
Inside Information / Other news releases
|
English | 85.1 KB | |
| 2025-05-13 22:00 |
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
|
French | 114.2 KB | |
| 2025-04-23 20:30 |
Pre-Annual General Meeting Information
Inside Information / Other news releases
|
English | 82.1 KB | |
| 2025-04-23 20:30 |
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
|
French | 113.3 KB | |
| 2025-04-08 15:55 |
Annual Report (ESEF)
URD 2024
|
English | 22.4 MB | |
| 2025-04-08 07:00 |
Report Publication Announcement
INSIDE INFORMATION / OTHER NEWS RELEASES
|
English | 88.3 KB |
Automate Your Workflow. Get a real-time feed of all GenSight Biologics S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for GenSight Biologics S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-09 | N/A | Other | Other | 5,063,291 | 1,999,999.95 EUR |
| 2024-02-07 | N/A | Other | Other | 5,224,660 | 1,999,999.85 EUR |
| 2023-11-21 | N/A | Other | Other | 3,038,279 | 2,163,862.30 EUR |
